Immunovant, Inc. — Director's Dealing 2023

Oct 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2023-10-19

Reporting Person: Macias William L. (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-19	Common Stock	S	530	$36.80	Disposed	336862	Direct

Footnotes

F1: On June 11, 2021, the holder was granted 18,674 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on June 15, 2021, of which 1,168 of these RSUs vested on October 13, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.